Ulum Bariş, Muljo Stefan A
Integrative Immunobiology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA.
Gene Technol. 2020;9(3).
Bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) is an archetype of cellular therapy. However, to date BMT still suffers from several complications. Recent technological advances have encouraged us to think about an alternative to traditional BMT. Specifically, we propose in utero HSCT (IUHSCT). For this purpose, we suggest that induced fetal-like hematopoietic stem cells (ifHSCs) might be suitable for IUHSCT, and should be seriously evaluated.
骨髓移植（BMT）或造血干细胞移植（HSCT）是细胞治疗的典范。然而，迄今为止，BMT仍存在多种并发症。最近的技术进步促使我们思考传统BMT的替代方法。具体而言，我们提出宫内造血干细胞移植（IUHSCT）。为此，我们认为诱导性类胎儿造血干细胞（ifHSCs）可能适用于IUHSCT，应予以认真评估。
